Christopher Bunker

Company: Alamar Biosciences Inc.

Job title: Vice President - Biopharma Business Development

Seminars:

NULISA CNS Disease Biomarker Platform 8:30 am

• The only high-plex, high sensitivity platform for investigation of biomarkers of neurodegenerative diseases and treatment response • NULISA™ combines ultra-sensitive femtogram level detection with barcode-based highplex biomarker analysis • The NULISA CNS Disease Panel is unique in enabling investigation of hundreds of proteins involved in neuroinflammation, vascular, and synaptic dysfunction, and proteinopathies • NULISA offers…Read more

day: Conference Day Two